Neogen (FRA:NG2) Cyclically Adjusted Revenue per Share: €4.36 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG2 Neogen Corp FRA:NG2
68 GF Score
Price €10.03
GF Value €9.63
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Neogen Cyclically Adjusted Revenue per Share?

Neogen FRA:NG2 +1.33% 68 Cyclically Adjusted Revenue per Share is €4.36 as of May. 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €9.63 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Neogen's adjusted revenue per share for the three months ended in May. 2026 was €0.886. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.36 for the trailing ten years ended in May. 2026.

During the past 12 months, Neogen's average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Neogen was 15.40% per year. The lowest was 2.70% per year. And the median was 12.70% per year.

As of today (2026-09-04), Neogen's current stock price is €10.03. Neogen's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was €4.36. Neogen's Cyclically Adjusted PS Ratio of today is 2.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neogen was 17.87. The lowest was 0.92. And the median was 10.14.


Neogen  (FRA:NG2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Neogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.03/4.36
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neogen was 17.87. The lowest was 0.92. And the median was 10.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Neogen Cyclically Adjusted Revenue per Share Related Terms


Neogen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Neogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Cyclically Adjusted Revenue per Share Chart

Neogen Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.80 3.99 4.36 4.43 4.36

Neogen Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 4.12 4.21 4.12 4.36

FRA:NG2 vs UFPT, AXGN, BFLY: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Neogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neogen's Cyclically Adjusted PS Ratio falls into.


FRA:NG2
68GF Score
Neogen Corp FRA:NG2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neogen's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0.886/335.1230*335.1230
=0.886

Current CPI (May. 2026) = 335.1230.

Neogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.733 240.849 1.020
201611 0.824 241.353 1.144
201702 0.808 243.603 1.112
201705 0.845 244.733 1.157
201708 0.774 245.519 1.056
201711 0.826 246.669 1.122
201802 0.736 248.991 0.991
201805 0.870 251.588 1.159
201808 0.817 252.146 1.086
201811 0.896 252.038 1.191
201902 0.820 252.776 1.087
201905 0.937 256.092 1.226
201908 0.865 256.558 1.130
201911 0.923 257.208 1.203
202002 0.863 258.678 1.118
202005 0.942 256.394 1.231
202008 0.867 259.918 1.118
202011 0.911 260.229 1.173
202102 0.899 263.014 1.145
202105 0.969 269.195 1.206
202108 1.009 273.567 1.236
202111 1.057 277.948 1.274
202202 1.045 283.716 1.234
202205 1.229 292.296 1.409
202208 1.211 296.171 1.370
202211 1.044 297.711 1.175
202302 0.942 300.840 1.049
202305 1.027 304.127 1.132
202308 0.968 307.026 1.057
202311 0.980 307.051 1.070
202402 0.979 310.326 1.057
202405 1.011 314.069 1.079
202408 0.908 314.796 0.967
202411 1.005 315.493 1.068
202502 0.978 319.082 1.027
202505 0.921 321.465 0.960
202508 0.827 323.976 0.855
202511 0.894 324.122 0.924
202602 0.821 326.785 0.842
202605 0.886 335.123 0.886

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.36 mean?
Neogen (FRA:NG2) has a Cyclically Adjusted Revenue per Share of €4.36 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Neogen and its competitors.
Is Neogen's Cyclically Adjusted Revenue per Share too high?
Neogen's current Cyclically Adjusted Revenue per Share is €4.36. Overall, Neogen has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Cyclically Adjusted Revenue per Share compare to UFPT and AXGN?
Neogen's Cyclically Adjusted Revenue per Share of €4.36 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Neogen and its competitors. Neogen's current Cyclically Adjusted Revenue per Share is €4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Fairly Valued. The stock's GF Value™ is €9.63, compared to a current price of €10.03 — trading 4.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.36. Neogen's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Cyclically Adjusted Revenue per Share is €4.36 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be overvalued. The current stock price of €10.03 is trading 4.2% above its estimated GF Value™ of €9.63. GuruFocus considers Neogen to be Fairly Valued.

Key valuation signals for FRA:NG2:

  • Cyclically Adjusted Revenue per Share: €4.36
  • GF Value™: €9.63 vs. price of €10.03 (4.2% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score

Get the complete analysis for FRA:NG2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.03
Price
€9.63
GF Value